LTA4H inhibitor LYS006: Clinical PK/PD and safety in a randomized phase I clinical trial

• Main Authors: Christian Loesche (Author), Damien Picard (Author), Benjamin Van Hoorick (Author), Imelda Schuhmann (Author), Petra Jäger (Author), Kai Klein (Author), Carole Schuhler (Author), Gebhard Thoma (Author), Christian Markert (Author), Birk Poller (Author), Natasa Zamurovic (Author), H. Markus Weiss (Author), Heike Otto (Author), Martin Fink (Author), Till A. Röhn (Author)
• Format: Book
• Published: Wiley, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract LYS006 is a novel, highly potent and selective, new‐generation leukotriene A4 hydrolase (LTA4H) inhibitor in clinical development for the treatment of neutrophil‐driven inflammatory diseases. We describe the complex pharmacokinetic to pharmacodynamic (PD) relationship in blood, plasma, and...